Preview

Rational Pharmacotherapy in Cardiology

Advanced search

PREDICTORS OF THE RISK OF HEMORRHAGIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION RECEIVING LONGTERM THERAPY WITH DIRECT ORAL ANTICOAGULANTS

https://doi.org/10.20996/1819-6446-2017-13-6-756-763

Full Text:

Abstract

Aim. To study the initial disorders in the coagulation system, as factors influencing the development of bleeding during anticoagulant therapy with direct oral anticoagulants (DOAC).

Material and methods. 117 patients receiving DOAC (direct thrombin inhibitors – dabigatran, and Xa factor inhibitors – rivaroxaban and apixaban) were included into the cohort study in parallel groups. In addition to evaluate the efficacy and safety of therapy, an extensive analysis of the blood hemostasis system was performed in patients before the start of anticoagulant therapy.

Results. No thromboembolic events and major bleedings were registered in patients receiving DOAC during 24 month observation. No significant correlations were observed between minor bleeding frequency in both groups (16.33% in dabigatran group and 22.39% in Xa factor inhibitors group) and troponin I and hemoglobin levels, as well as HAS-BLED and ATRIA risk scores. Among patients receiving dabigatran initial decrease in von Willebrand factor plasma level (p=0.02) and increase in fibrinogen blood concentration (p=0.02) were predictors of minor bleedings. These predictors of bleeding events were not found in Xa inhibitor groups.

Conclusions. DOAC in patients with atrial fibrillation showed their efficacy and safety without any differences between classes of direct thrombin inhibitors and Xa factor inhibitors. Among the possible predictors of spontaneous minor hemorrhagic events on the dabigatran therapy, a reduced level of von Willebrand factor and elevated fibrinogen level may be considered when choosing a dose of the drug. Markers of hemorrhagic complications development were not determined for the Xa factor inhibitors. Limitation of this study was the absence of randomization, that is why the results should be interpreted with caution.

About the Authors

A. А. Sokolova
I.M. Sechenov First Moscow State Medical University
Russian Federation

Anastasiya A. Sokolova – MD, PhD, Assistant, Chair of Faculty Therapy №1, Medical Faculty 

Trubetskaya ul. 8-2, Moscow, 119991



A. V. Zhilenko
I.M. Sechenov First Moscow State Medical University
Russian Federation

Anna V. Zhilenko – MD, Cardiologist, Treatment and Diagnostic Unit, University Clinical Hospital №1 

Trubetskaya ul. 8-2, Moscow, 119991



I. L. Tsarev,
I.M. Sechenov First Moscow State Medical University
Russian Federation

Ivan L. Tsarev – MD, Resident, Chair of Clinical Pharmacology and Pharmacotherapy 

Trubetskaya ul. 8-2, Moscow, 119991



D. A. Napalkov
I.M. Sechenov First Moscow State Medical University
Russian Federation

Dmitry A. Napalkov – MD, PhD, Professor, Chair of Faculty Therapy №1, Medical Faculty 

Trubetskaya ul. 8-2, Moscow, 119991



V. V. Fomin
I.M. Sechenov First Moscow State Medical University
Russian Federation

Viktor V. Fomin – MD, PhD, Professor, Corresponding Member of the Russian Academy of Sciences, Head of Chair of Faculty Therapy №1, Medical Faculty 

Trubetskaya ul. 8-2, Moscow, 119991



References

1. Westendorf J., Ageno W. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism. Thromb Haemost. 2014;16:113-128. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals; 2011.

2. Diagnosis and treatment of atrial fibrillation. Recommendations of the Russian Cardiological Society, All-Russian Scientific Society of Clinical Electrophysiology, Arrhythmology and Pacemakers, Association of Cardiovascular Surgeons. Available at: www.scardio.ru/content/Guidelines/FP_rkj_13.pdf. Checked on 12/7/2017. (In Russ.) [Диагностика и лечение фибрилляции предсердий. Рекомендации Российского кардиологического общества, Всероссийского научного общества специалистов по клинической электрофизиологии, аритмологии и кардиостимуляции, Ассоциации сердечно-сосудистых хирургов. Доступно на: www.scardio.ru/content/Guidelines/FP_rkj_13.pdf. Проверено 07.12.2017].

3. Heidenreich P.A., Solis P., Estes N.A. 3rd, et al. 2016 ACC/AHA Clinical Performance and Quality Measures for Adults With Atrial Fibrillation or Atrial Flutter: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. J Am Coll Cardiol. 2016 Aug 2;68(5):525-68. doi: 10.1016/j.jacc.2016.03.521.

4. Heidbuchel H., Verhamme P., Alings M., et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015;17(10):1467-507. doi: 10.1093/europace/euv309.

5. Lip G.Y.H., Laroche C., Popescu M.I., et al. Prognosis and treatment of atrial fibrillation patients by European cardiologists: One Year Follow-up of the EUROobservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot Registry. Eur Heart J. 2014;35:3365-76. doi: 10.1093/eurheartj/ehu374.

6. Patel M.R., Mahaffey K.W., Garg J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-91. doi: 10.1056/NEJMoa1009638.

7. Granger C.B., Alexander J.H., McMurray J.J., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-92. doi: 10.1056/NEJMoa1107039.

8. Connolly S.J., Eikelboom J., Joyner C., et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806-17. doi: 10.1056/NEJMoa1007432.

9. Ng K.H., Hart R.G., Eikelboom J.W. Anticoagulation in patients with atrial fibrillation: role of novel oral anticoagulants. Cardiol Ther. 2013;2:135-14. doi: 10.1007/s40119-013-0019-y.

10. Lip G.Y.H., Laroche C., Popescu M.I., et al. Prognosis and treatment of atrial fibrillation patients by European cardiologists: One Year Follow-up of the EUROobservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot Registry). Eur Heart J. 2014;35:3365-76. doi: 10.1093/eurheartj/ehu374.


For citation:


Sokolova A.А., Zhilenko A.V., Tsarev, I.L., Napalkov D.A., Fomin V.V. PREDICTORS OF THE RISK OF HEMORRHAGIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION RECEIVING LONGTERM THERAPY WITH DIRECT ORAL ANTICOAGULANTS. Rational Pharmacotherapy in Cardiology. 2017;13(6):756-763. (In Russ.) https://doi.org/10.20996/1819-6446-2017-13-6-756-763

Views: 242


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)